Clinical Trial Update: A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating the combination of pembrolizumab and lenvatinib in PD-L1 positive, TKI-resistant non-small cell lung cancer, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING